Company record · updated October 7, 2026
Scilex Holding Co: 2 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs July 31, 2024 to October 31, 2024.
2observations
2source filings
2verified rows
2024-10-31most recent as-of date
Source rails for this company: N-PORT fund mark (2).
Reported by 1 filer: Virtus LifeSci Biotech Clinical Trials ETF.
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2024-10-31 | price per share | 0.8643 USD | Virtus LifeSci Biotech Clinical Trials ETF | VERIFIED | valUSD 15518.51 / balance 17955.0 [unspecified] | 000175272424288174 |
| 2024-07-31 | price per share | 1.431 USD | Virtus LifeSci Biotech Clinical Trials ETF | VERIFIED | valUSD 25235.69 / balance 17635.0 [unspecified] | 000175272424222960 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price.